BioOutsource Expands ADC Characterisation Capabilities
![](/46/pdcnewsitem/03/30/70/7dTmNp7JhcXNcSU.png)
BioOutsource Ltd, a leading international contract testing organisation (CTO) has amplified its position as a global leader in antibody drug conjugates (ADC) characterisation and is pleased to announce a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon-Tyne that specialises in the development of next-generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.
“Building on our position as a leader in biological characterisation of monoclonal antibodies, ADCs represent an exciting development which will enhance the performance of a wide range of therapeutic products. We are delighted to partner with Glythera to characterise their ADC product in development, as we believe it holds considerable promise,” commented BioOutsource CSO, Daniel Galbraith.
Chief Operating Officer at Glythera Dr David Simpson, highlighted the value of the collaboration: “we are delighted to have the opportunity to work with BioOutsource on their ADC characterisation as it is an area where our linker technologies offer significant benefits. This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”
BioOutsource has also announced that it will be exhibiting at the World ADC Summit, 17–20 February in Frankfurt, in partnership with Aptuit, Glasgow, a pharmaceutical services company, and with support from Scottish Development International (SDI).
“We are eagerly anticipating exhibiting at the World ADC Summit in Frankfurt,” continued Dr Galbraith. “In partnership with Aptuit and with generous support from Scottish Development International, we welcome the opportunity to demonstrate our expertise in ADC characterisation.”
More information on the World ADC Summit is available at http://adcsummit-europe.com
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance